Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 24, Issue 1, Pages 33-44
Publisher
Elsevier BV
Online
2022-11-30
DOI
10.1016/s1470-2045(22)00687-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
- (2022) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
- (2022) Alessandro Nepote et al. Journal of Clinical Medicine
- Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
- (2022) Julia R. Dixon-Douglas et al. Current Oncology Reports
- First‐line atezolizumab monotherapy in patients with advanced BRAF V600 wild‐type melanoma
- (2021) Sergio Jobim de Azevedo et al. Pigment Cell & Melanoma Research
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
- (2020) Reinhard Dummer et al. JAMA Oncology
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
- (2020) Pier Francesco Ferrucci et al. Journal for ImmunoTherapy of Cancer
- Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab
- (2019) Omid Hamid et al. CLINICAL CANCER RESEARCH
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
- (2016) Teresa Amaral et al. Expert Review of Anticancer Therapy
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
- (2014) J. A. Wargo et al. Cancer Discovery
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
- (2010) Stephen B. Edge et al. ANNALS OF SURGICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search